[Acarbose, a reliable therapeutic principle].

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Type 2 diabetes management requires effective glycemic control, especially for patients with high postprandial glucose.
• Dietary interventions alone are often insufficient for achieving target glycemic control.
• Acarbose is a recognized first-line treatment option for specific patient profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of acarbose in managing type 2 diabetes.
• To assess the impact of acarbose on glycated hemoglobin (HbA1c) and metabolic syndrome parameters.
• To determine the effect of acarbose on cardiovascular endpoints in patients with impaired glucose tolerance.

Main Methods:

• Acarbose administered as monotherapy and in combination with other antidiabetic agents.
• Assessment of blood glucose levels and glycated hemoglobin (HbA1c).
• Evaluation of metabolic syndrome parameters and cardiovascular endpoints.

Main Results:

• Acarbose reliably reduces HbA1c levels by 0.9% and improves metabolic syndrome parameters.
• Significant 49% reduction in cardiovascular endpoints observed in patients with impaired glucose tolerance.
• No serious adverse effects reported; gastrointestinal side effects manageable with dose adjustment and dietary adherence.

Conclusions:

• Acarbose is an effective first-line treatment for type 2 diabetes, improving glycemic control and metabolic parameters.
• Acarbose demonstrates significant cardiovascular benefits in patients with impaired glucose tolerance.
• The drug is well-tolerated, with manageable side effects, making it a valuable therapeutic option.